meta
|
evidence
oncology
Living systematic review and meta-analysis
metastatic/advanced - esophageal cancer (mEC)
mEC - (neo)adjuvant (NA)
1
mEC - 1st line (L1)
1
mEC - 2nd line (L2)
3
gastric or gastroesophageal junction cancer (GC)
immune chekpoint inhibitors
anti-PD-(L)1
nivolumab based treatment
nivolumab alone
versus all
vs non active control
vs no additional treatment
vs placebo
study list
mapping
overview
meta-analysis
forest plot
NMA
excluded
graph
EGM
comparisons
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
nivolumab alone
title
placebo
title
CheckMate 577, 2021 NCT02743494 mEC - (neo)adjuvant (NA) 532/262
Pathology:
mEC - (neo)adjuvant (NA);
mEC - (neo)adjuvant (NA)
CheckMate 577, 2021
nivolumab alone
1
T1
placebo
0
T0